STOCK TITAN

SAB Biotherapeutics, Inc. (SABS) Revenue by Year

SABS

SAB Biotherapeutics, Inc. generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior fiscal year. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters SAB Biotherapeutics, Inc. has filed alongside them.

FY2025 annual
Revenue $0
YoY -100.0%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

SABS Revenue by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-K
Revenue$0-100.0%$1.3M-40.9%$2.2M-90.6%$23.9M-60.7%$60.9M+10.2%$55.2M

SABS Revenue by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
RevenueN/AN/AN/AN/AN/AN/AN/AN/A$263K+207.7%$945K+62.5%$305K-85.9%$1.3M-64.7%

What revenue means

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it.

More SAB Biotherapeutics, Inc. financials

Frequently Asked Questions

What was SAB Biotherapeutics, Inc.'s revenue in fiscal year 2025?

SAB Biotherapeutics, Inc. generated $0 in revenue in fiscal year 2025.

How fast is SAB Biotherapeutics, Inc.'s revenue growing?

SAB Biotherapeutics, Inc. (SABS) revenue fell by 100.0% year over year, from $1.3M to $0 in fiscal year 2025.

How has SAB Biotherapeutics, Inc.'s revenue changed over the years?

Across the 6 fiscal years this page covers, SAB Biotherapeutics, Inc. (SABS) revenue went from $55.2M in fiscal year 2020 to $0 in fiscal year 2025.

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it. This page lists what SAB Biotherapeutics, Inc. (SABS) reported on that line in every period on record.